Segment Information (Details) - Schedule of Reportable Segments - Reportable Subsegments [Member] - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Sales	$ 1,172,601	$ 1,033,925	$ 3,314,663	$ 1,824,496
Cost of sales	883,143	841,414	2,416,417	1,415,068
Inventory write-down			263,404	576,772
Gross profit	289,458	192,511	634,842	(167,344)
Research and development and patents	656,764	878,303	2,558,648	3,108,312
General and administrative	1,374,095	1,412,727	4,036,784	4,438,083
Amortization and depreciation	54,767	50,689	164,833	148,786
Other expense	48,156	2,733	36,717	79,287
Total operating expenses	2,133,782	2,344,452	6,796,982	7,774,468
Other income (expense)	121,458	155,497	424,261	343,881
Tax expense		(1,500)		(11,300)
Net loss	(1,722,866)	(1,997,944)	(5,737,879)	(7,609,231)
Unrestricted cash	7,600,598	9,604,057	7,600,598	9,604,057
InMed Pharma [Member]
Segment Reporting Information [Line Items]
Sales
Cost of sales
Inventory write-down
Gross profit
Research and development and patents	620,223	870,837	2,458,576	2,991,525
General and administrative	1,172,023	1,213,047	3,434,917	3,854,275
Amortization and depreciation	54,168	50,261	163,045	147,754
Other expense	48,156	2,733	36,717	79,242
Total operating expenses	1,894,570	2,136,878	6,093,255	7,072,796
Other income (expense)	102,987	155,567	424,480	344,083
Net loss	(1,791,583)	(1,981,311)	(5,668,775)	(6,728,713)
Unrestricted cash	6,578,230	9,441,977	6,578,230	9,441,977
BayMedica Commercial [Member]
Segment Reporting Information [Line Items]
Sales	1,172,601	1,033,925	3,314,663	1,824,496
Cost of sales	883,143	841,414	2,416,417	1,415,068
Inventory write-down			263,404	576,772
Gross profit	289,458	192,511	634,842	(167,344)
Research and development and patents	36,541	7,466	100,072	116,787
General and administrative	202,072	199,680	601,867	583,808
Amortization and depreciation	599	428	1,788	1,032
Other expense				45
Total operating expenses	239,212	207,574	703,727	701,672
Other income (expense)	18,471	(70)	(219)	(202)
Tax expense		(1,500)		(11,300)
Net loss	68,717	(15,133)	(69,104)	(869,218)
Unrestricted cash	$ 1,022,368	$ 162,080	$ 1,022,368	$ 162,080